SOPHiA GENETICS SA Ordinary Shares (SOPH) Stock
Key stats
- Market cap
- $639.44M
- Price / Earnings ratio
- -8.3x
- EPS (TTM)
- -$1.09
- Volume
- Loading
- 52-week high
- $8.98
- 52-week low
- $3.83
Source: third-party data provider, as of November 13, 2026
Compare with SOPH
Recent news

SOPHiA GENETICS Q3 Earnings Call Highlights
SOPHiA GENETICS Q3 Earnings Call Highlights
SOPH

SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue Estimates
SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue Estimates
SOPH

SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?
SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?
SOPH

When Unusual Volume Isn't Noise: 3 Small-Caps Sending Signals
When Unusual Volume Isn't Noise: 3 Small-Caps Sending Signals
SOPH
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 50.85
- MACD 12/26/9
- -0.05
- EMA 9 of MACD
- -0.10
- MACD histogram
- 0.05
- SMA 50
- $7.66
- Price below SMA 50
- EMA 50
- $7.41
- Price above EMA 50
- SMA 200
- $6.02
- Price above SMA 200
- EMA 200
- $6.22
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

SOPHiA GENETICS Q3 Earnings Call Highlights
SOPHiA GENETICS Q3 Earnings Call Highlights
SOPH

SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue Estimates
SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue Estimates
SOPH

SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?
SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?
SOPH

When Unusual Volume Isn't Noise: 3 Small-Caps Sending Signals
When Unusual Volume Isn't Noise: 3 Small-Caps Sending Signals
SOPH

SOPHiA GENETICS Q2 Earnings Call Highlights
SOPHiA GENETICS Q2 Earnings Call Highlights
SOPH

SOPH Stock Heads For Best Day In Over 8 Months – What’s Driving Today’s Super Rally?
SOPH Stock Heads For Best Day In Over 8 Months – What’s Driving Today’s Super Rally?
SOPH

SOPHiA GENETICS Expands Partnership With AstraZeneca to Include Multimodal Approaches for Cancer Drug Development
SOPHiA GENETICS Expands Partnership With AstraZeneca to Include Multimodal Approaches for Cancer Drug Development
SOPH
News tone: automated (AI) classification of the article's content, not a price prediction.
About SOPHiA GENETICS SA Ordinary Shares
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Ross Jordan Muken B.Sc. | CEO & Director | 1980 |
| Dr. Jurgi Camblong M.B.A., Ph.D. | Co-Founder & Executive Chairman | 1978 |
| Mr. George A. Cardoza M.B.A. | Executive VP & CFO | 1962 |
| Mr. Abhimanyu Verma | EVP & Chief Technology Officer | — |
| Dr. Zhenyu Xu Ph.D. | Executive VP & Chief Scientific Officer | 1983 |
| Kellen Sanger | Head of Strategy and Investor Relations | — |
| Mr. Daan van Well L.L.M., M.B.A. | Executive VP and Chief Legal & Compliance Officer | 1975 |
| Mr. Kevin Puylaert | SVP & Chief Sales Officer | — |
| Ms. Manuela Da Silva Valente B.A. | Executive VP & Chief People Officer | 1971 |
| Dr. Philippe Menu M.B.A., M.D., Ph.D. | Executive VP, Chief Medical Officer & Chief Product Officer | 1982 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 50.85
- MACD 12/26/9
- -0.05
- EMA 9 of MACD
- -0.10
- MACD histogram
- 0.05
- SMA 50
- $7.66
- Price below SMA 50
- EMA 50
- $7.41
- Price above EMA 50
- SMA 200
- $6.02
- Price above SMA 200
- EMA 200
- $6.22
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $14.00
- Average
- $14.00
- High
- $14.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.8 | -0.6 | -5.0 | +5.1 |



